DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Robatumumab
Robatumumab
IGF System in Sarcomas: a Crucial Pathway with Many Unknowns to Exploit for Therapy
A Fully Human Insulin-Like Growth Factor-I Receptor Antibody SCH
Therapeutic Targeting of the IGF Axis
The Two Tontti Tudiul Lui Hi Ha Unit
The IGF-II–Insulin Receptor Isoform-A Autocrine Signal in Cancer: Actionable Perspectives
Prognostic and Therapeutic Utility of Variably Expressed Cell Surface
Ep 3321281 A1
Prescrire's Response
Receptor Tyrosine Kinase-Targeted Cancer Therapy
Focus on Approved and In-Clinical-Trial Monoclonal Antibodies
INN Working Document 05.179 Update 2011
Stembook 2018.Pdf
NETTER, Jr., Robert, C. Et Al.; Dann, Dorf- (21) International Application
INN Working Document 05.179 Update December 2010
IUPAC Glossary of Terms Used in Immunotoxicology (IUPAC Recommendations 2012)*
Focus on Approved and In-Clinical-Trial Monoclonal Antibodies
WO 2013/169611 Al 14 November 2013 (14.11.2013) P O P C T
(12) Patent Application Publication (10) Pub. No.: US 2017/0203043 A1 Rusch Et Al
Top View
(INN) for Biological and Biotechnological Substances
WO 2018/067987 Al 12 April 2018 (12.04.2018) W !P O PCT
Role of Immunotherapy in Ewing Sarcoma
6.6.2018 a Abacavir Abacavirum Abakaviiri Abagovomab
This Is an Author Produced Version of a Paper Published in Current Drug Targets
International Nonproprietary Names (INN) for Biological and Biotechnological Substances
Anti-IGF-1R Monoclonal Antibody
231 Targeting EGFR and IGF 1R
Assessment of the Evolution of Cancer Treatment Therapies
IGF-1R/Mtor Targeted Therapy for Ewing Sarcoma: a Meta-Analysis of Five IGF-1R-Related Trials Matched to Proteomic and Radiologic Predictive Biomarkers
Identification of Therapeutic Targets in Ovarian Cancer Through Active Tyrosine Kinase Profiling
Unraveling the Resistance of IGF-Pathway Inhibition in Ewing Sarcoma
International Nonproprietary Names for Pharmaceutical Substances (INN)
Monoclonal Antibodies and Chimeric Antigen Receptor
Combination Therapy Approaches to Target Insulin-Like Growth Factor Receptor Signaling in Breast Cancer
(12) Patent Application Publication (10) Pub. No.: US 2017/0173267 A1 Ashmead Et Al
(12) Patent Application Publication (10) Pub. No.: US 2015/0322155A1 Zhao (43) Pub
Supplementary Tables and Figures Section 1. Distribution of CDR-H3
(2006.01) C07d 413/14
( 12 ) Patent Application Publication
Pfizer Halts Trial of Industry's Most Advanced IGF-1R Antibody
IGF-1R/Mtor Targeted Therapy for Ewing Sarcoma: a Meta-Analysis of Five IGF-1R- Related Trials Matched to Proteomic and Radiologic Predictive Biomarkers
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
Cancer PRESENTEDBYAMERICA ’ SBIOPHARMACEUTICALRESEARCHCOMPANIES Nearly 900 Medicines and Vaccines in Testing Offer Hope in the Fight Against Cancer
(INN) for Biological and Biotechnological Substances
Targeting Obesity-Related Dysfunction in Hormonally Driven Cancers
The Role of the Insulin-Like Growth Factor Axis in Osseous Metastasis
Truncated Epiderimal Growth Factor Receptor (Egfrt) for Transduced T Cell Selection
Targeting the Insulin-Like Growth Factor-1 Receptor in Human Cancer
Oncology Drugs in the Pipeline
Timepoint 1 Geting Assembly Complexes (Attacs) for Selectively Activating De¬ Sired Immune Cells in the Tumor Microenvironment
Comprehensive Review of Targeted Therapy for Colorectal Cancer
Differential Effects of IGF-1R Small Molecule Tyrosine Kinase Inhibitors
Schering-Plough Corporation 2000 Galloping Hill Road Kenilworth, NJ, 07033-0530